Spencer Brown D., the Senior Vice President and General Counsel of PDS Biotechnology Corp, has exercised 150,000 employee stock options. This significant move highlights Brown's confidence in the company's prospects, particularly as it navigates the competitive landscape of the pharmaceutical preparations industry.
PDS Biotechnology Corp, incorporated in Delaware, operates within the pharmaceutical preparations sector, focusing on innovative therapies. The company is listed under the Central Index Key number 0001472091 and is known for its commitment to advancing biotechnology solutions.
The recent filing indicates that the stock options were granted on November 16, 2026, and are subject to stockholder approval of the company's 2026 Equity Incentive Plan. According to the filing, "The option is not exercisable until stockholder approval has been obtained." If stockholder approval is granted, the shares will vest in equal monthly installments over four years, beginning December 16, 2026, contingent upon Brown's continued service with the company.
This development may impact various stakeholders, including company executives, employees, and shareholders, as it reflects a potential alignment of interests between management and investors. The filing suggests that if stockholder approval is not obtained, Brown will surrender the option for cancellation.
Details were not available in the SEC filing regarding any upcoming votes or additional filings related to this matter. The filing can be referenced under accession number 0001140361-26-044528.
Read Next
Peloton CEO Peter C. Stern Reports Major Stock Transactions
Sullivan Haas Reports Share Forfeiture for Tax Obligations
CFO Gephart Brian Reports Share Forfeiture at Magnite, Inc.
Chung Nicholas Reports Stock Transactions for Moog Inc.
Magnite Chief Legal Officer Reports Stock Transaction
Mclachlan Stuart Reports Stock Transactions at Moog Inc.









